Xu, ChenxiTsai, Yi-HsuanGalbo, Phillip MGong, WeidaStorey, Aaron JXu, YuemeiByrum, Stephanie DXu, LingfanWhang, Young EParker, Joel SMackintosh, Samuel GEdmondson, Ricky DTackett, Alan JHuang, JiaotiZheng, DeyouEarp, H SheltonWang, Gang GregCai, Ling2023-09-082023-09-082021-050305-10481362-4962https://hdl.handle.net/10161/28978Castration-resistant prostate cancer (CRPC) is a terminal disease and the molecular underpinnings of CRPC development need to be better understood in order to improve its treatment. Here, we report that a transcription factor Yin Yang 1 (YY1) is significantly overexpressed during prostate cancer progression. Functional and cistrome studies of YY1 uncover its roles in promoting prostate oncogenesis in vitro and in vivo, as well as sustaining tumor metabolism including the Warburg effect and mitochondria respiration. Additionally, our integrated genomics and interactome profiling in prostate tumor show that YY1 and bromodomain-containing proteins (BRD2/4) co-occupy a majority of gene-regulatory elements, coactivating downstream targets. Via gene loss-of-function and rescue studies and mutagenesis of YY1-bound cis-elements, we unveil an oncogenic pathway in which YY1 directly binds and activates PFKP, a gene encoding the rate-limiting enzyme for glycolysis, significantly contributing to the YY1-enforced Warburg effect and malignant growth. Altogether, this study supports a master regulator role for YY1 in prostate tumorigenesis and reveals a YY1:BRD2/4-PFKP axis operating in advanced prostate cancer with implications for therapy.Cell Line, TumorAnimalsHumansMice, SCIDPhosphofructokinase-1, Type CCell Cycle ProteinsTranscription FactorsGene Expression Regulation, NeoplasticGlycolysisMaleYY1 Transcription FactorTranscriptional ActivationHEK293 CellsProstatic Neoplasms, Castration-ResistantCarcinogenesisJournal article2023-09-08